Related Experiment Videos
Apheresis techniques in lymphokine-activated killer cell production
I Sniecinski1, K Sentinella, K Margolin
1Blood Transfusion Services, City of Hope National Medical Center, Duarte, CA 91010.
Journal of Clinical Apheresis
|January 1, 1988
Summary
This study evaluated the effectiveness of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) therapy in advanced cancer patients. The research focused on apheresis technology for generating potent cytotoxic cells for adoptive transfer.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Adoptive transfer of lymphokine-activated killer (LAK) cells with recombinant interleukin-2 (rIL-2) has shown promise in treating metastatic cancer.
- Previous studies reported significant regression in advanced cancer patients using this regimen.
Purpose of the Study:
- To confirm the efficacy of the IL-2/LAK regimen at multiple cancer centers.
- To detail the process of mononuclear cell isolation and expansion for adoptive immunotherapy.
Main Methods:
- Utilized apheresis technology for mononuclear cell collection from cancer patients.
- Employed extracorporeal handling techniques to generate a selective, highly cytotoxic cell population.
- Administered the established IL-2/LAK regimen across six extramural cancer centers.
Main Results:
- The study reviewed the experience of using apheresis and extracorporeal cell handling.
- Focused on the generation of a potent cytotoxic cell population for cancer treatment.
- The report details the methodology applied in the multi-center trial.
Conclusions:
- The findings support the review of experiences with IL-2/LAK therapy in advanced cancer.
- Highlights the role of apheresis technology in preparing cells for adoptive immunotherapy.
- Further investigation into this therapeutic approach for metastatic disease is warranted.